FDA Authorizes Phagenesis’ Phagenyx System

The FDA has granted de novo authorization to Phagenesis’ Phagenyx electrical stimulation system for treatment of stroke patients who have difficulty in swallowing.

The system delivers electrical stimulation to the oropharynx, part of the throat at the back of the mouth behind the oral cavity.

The UK-based company is focused on the development of novel therapies to treat patients with neurogenic dysphagia, swallowing disorders caused by diseases of the central and peripheral nervous system.